Assessment measures
peripheral motor function, processFACT-Taxane, toxicity, paresthesia, CIPN, dysesthesia, neuralgia
ADVERSE EVENTS, SECONDARY, SENSORY NEUROPATHY, PARESTHESIA
The primary outcome will be the percentage of patients with a significant decrease in FACT-NTX scores before the paclitaxel course (baseline) and after the paclitaxel chemotherapy course (target) [AIUR trial: Study designThe time frame will be divided into four periods (Fig. Diagram for the study time processFACT-Taxane is a self-report instrument developed to measure the health-related QoL of patients receiving taxane-containing chemotherapy. FACT-Taxane comprises FACT-General (FACT-G) [The secondary outcomes will be changes in FACT-Taxane and NCI-CTCAE scores for CIPN at baseline, during chemotherapy, at the target time frame, and 6 months after completion of the paclitaxel course. The NCI-CTCAE version 5.0 for CIPN is a method for reporting the severity of adverse events using a combination of clinical evaluations. These adverse events include peripheral motor function, sensory neuropathy, dysesthesia, paresthesia, neuralgia, and skin/nail toxicity. Participants will also be checked for comfort using the intervention scale score during the course of paclitaxel, at the target timeframe, and 6 months later.The participants will not proceed with self-reporting alone, as the attending physician or research nurse will always assist the patients with the questionnaire.